Measuring What Can't Be Seen: How PTSD Clinical Trials Prove A Drug Works

PTSD trials expose one of the hardest problems in modern drug development: measuring subjective human experience with scientific rigor. Unlike oncology, where outcomes are often visible and binary, PTSD studies rely on clinician-administered and patient-reported scales such as the CAPS-5 to determine whether a therapy truly works. These instruments form the backbone of modern registration trials, yet they are inherently vulnerable to placebo response, expectancy bias, and functional unblinding. The challenge becomes especially acute in psychedelic research, where participants frequently recognize whether they received the active drug, potentially influencing the very endpoints used to establish efficacy. As recent FDA scrutiny of MDMA-assisted therapy demonstrated, statistical significance alone is no longer enough. Trial design, blinding integrity, endpoint selection, and rater strategy have become central determinants of regulatory credibility in the next generation of PTSD therapeutics.